目的：比较舒巴坦钠／头孢哌酮钠（海舒必）与头孢曲松钠（罗塞秦）治疗下呼吸道感染的疗效、细菌清除率和不良反应。方法：采用随机分组对照方法，海舒必组４６例，２～４ｇ／ｄ，静滴，ｂｉｄ，５～１４ｄ为一疗程；罗塞秦组４９例，２ｇ／ｄ，ｑｄ或２～４ｇ／ｄ，ｂｉｄ，５～１４ｄ为一疗程。结果：海舒必组有效率为８９．１％，细菌清除率为８３．３％，不良反应发生率为４．３％；罗塞秦组有效率为８４．８％，细菌清除率为８０．８％，不良反应发生率为１８．４％。结论：两组在治疗下呼吸道感染的有效率及细菌清除率方面无显著差异，但罗塞秦组的不良反应明显高于海舒必组，有显著差异，因此海舒必比罗塞秦不良反应少，使用更安全 OBJECTIVE: To compare the efficacy of sulbactam / cefoperazone sodium (Cefoperazone) with ceftriaxone sodium (Rosetzin) in the treatment of lower respiratory tract infections, bacterial clearance and adverse reactions. Methods: Forty-six patients (2g / d, qd or 2-4g / d) were treated with Rosiglitazone in a randomized controlled trial. d, bid, 5 ~ 14d for a course of treatment. Results: The effective rate was 89.1%, the bacterial clearance rate was 83.3%, the adverse reaction rate was 4.3%, the effective rate was 84.8% in Rosuvastatin group and the bacterial clearance rate was 80 .8%, the incidence of adverse reactions was 18.4%. Conclusion: There is no significant difference between the two groups in the treatment of lower respiratory tract infection and bacterial clearance rate, but the adverse reactions in Rosetzin group were significantly higher than those in the control group Less, safer to use